Scientific Advisory

Marc Bailie, DVM, PhD, DSP | Independent Member

With nearly 25 years of experience in drug discovery and development, Dr. Bailie’s expertise includes an array of models to evaluate the pharmacologic and toxicologic activity of compounds. As Director of the In Vivo Pharmacology Facility at Michigan State University, he leads a team that provides pharmacology and early safety testing to academic and private sector investigators. He concurrently serves as partner and Chief Development Officer of Integrated Nonclinical Development Solutions Inc. (INDS), a consulting group that offers strategic and tactical support for drug discovery and development projects.

Dr. Bailie spent 11 years with Parke-Davis/Pfizer developing and directing the Safety Pharmacology Group within Drug Safety Research and Development. He served on numerous discovery and development project teams, was involved in several projects that progressed to New Drug Application (NDA) with the FDA. Dr. Bailie has published over 35 papers in peer-reviewed journals, is a certified Diplomate in Safety Pharmacology (DSP) and earned both his doctor of veterinary medicine and Ph.D. from Michigan State University.

 

Ann R. Donoghue, DVM, MS | Independent Member

Dr. Donoghue is a leading expert with over 25 years of experience in the development and registration of veterinary and human pharmaceuticals and veterinary diagnostic tests. Prior to serving as an independent consultant, she held various leadership positions with Hoechst-Roussel Agri-Vet Company, Heska Corporation, PR Pharmaceuticals, Inc. and Michigan State University Animal Health Diagnostic Laboratory.

Under Dr. Donoghue’s leadership, project teams have obtained approvals for USDA licensed diagnostic test kits, New Animal Drug Applications (NADAs), and an EPA registered pesticide. Her other noteworthy experience includes FDA pre-approval inspections, GLP study site audits, GCP clinical trial activities, and FDA pre-submission conferences. She obtained an Orphan Drug Designation and completed a subsequent Investigational New Drug (IND) application resulting in a successful phase I clinical trial less than one year from project initiation. A regular reviewer for the Journal of the American Veterinary Medical Association and the American Journal of Veterinary Research, Dr. Donoghue received her doctor of veterinary medicine, Master of Science, and Bachelor of Science from Michigan State University.

 

Angy Guerrant | Director of Portfolio Management

As Zomedica’s Director of Portfolio Management, Angy Guerrant is responsible for keeping product innovations on track, within budget, and in-line with company goals and objectives to deliver safe, effective and affordable products that help veterinarians better serve the animal in their care.

Angy has built her 15-year career on the foundation of successfully leading corporate business initiatives that directly impact the bottom line. During her tenure with MPI Research, she increased annual revenue by $9.6 million by establishing and enforcing key policies while capturing scope changes impacting budgets. She quickly established a reputation for expertly sourcing and forecasting capacity over a diverse project portfolio, managing 544 research rooms and over 700 employees across 1,800 active projects with durations ranging from months to years. Angy earned her Bachelor of Science in biomedical science from Western Michigan University and is a Certified Laboratory Animal Technologist.

 

William C. MacArthur, MS, DVM | Chief Medical Officer, Director of R&D

Dr. MacArthur is Zomedica’s Chief Medical Officer and Director of R&D and serves on the company’s Board of Directors. He converges his first-hand experience in clinical veterinary practice with his animal biotechnology expertise to develop high-value products that address the unmet needs of companion animal veterinarians.

Prior to joining Zomedica, Dr. MacArthur was the founder, CEO and Institutional Veterinarian of the small cap biotechnology startup GeneWorks, which established a post-money valuation of $35 million. He subsequently opened and presently operates a four-doctor small animal clinical practice, where he excels at solving difficult diagnoses. Dr. MacArthur earned Bachelor of Science degrees in zoology, biochemistry, and chemistry from the University of Massachusetts Amherst, a Master of Science in cellular and molecular biology from the University of Michigan, and doctor of veterinary medicine from Michigan State University.

 

Stephanie L. Morley, DVM | Chief Operations Officer

As Zomedica’s Chief Operations Officer, Dr. Morley is developing and aligning core systems and lean business operations to effectively serve the company’s vision and mission. With 15 years of experience in clinical veterinary practice, operational leadership and business development, she is astutely qualified to build a credible business that both veterinarians and investors believe in and value.

After earning a Bachelor of Arts in hospitality business and doctor of veterinary medicine from Michigan State University, Dr. Morley was a practicing veterinarian with multiple veterinary clinics where she quickly learned to juggle the roles of both clinical practitioner and operations management. She then joined MPI Research and quickly advanced from supervisory roles to Vice President of Operations before leaving to join the University of Michigan Medical School as Associate Director of Business Development, where she facilitated strategic relationships between researchers and industry partners.